jRCT2080220721未知2 期
Phase II Study of 0.15% UF-021 in patients with retinitis pigmentosa
试验速览
- 阶段
- 2 期
- 入组人数
- 105
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Multicenter, randomized, double-blind, parallel-three groups study
入排标准
- 年龄范围
- 20age old over 至 65age old under（—）
- 性别
- All
入选标准
- •Decimal visual acuity: 0.5 or better
- •With abnormal visual field measured by the Goldmann perimetry
排除标准
- •The subject has taken steroids and/or vasodilators within 1 month prior to informed consent.
结局指标
主要结局
-
Efficacy and safety
次要结局
未报告次要终点
研究者
相似试验
未知
2 期
Phase II Study of 0.15% UF-021 in patients with retinitis pigmentosaretinitis pigmentosaJPRN-jRCT2080220721R-Tech Ueno, Ltd105
已完成
不适用
Phase I randomized study of 0.15% UF-021 in patients with geographic atrophy treated after wet age-related macular degeneratioAge-related macular degeneraitonJPRN-UMIN000007881Dept. of Ophthalmology, Kagawa university faculty of medicine50
进行中（未招募）
不适用
study in patients with refractory, metastatic cancer harboring KIT mutation or amplification to investigate the clinical efficacy and safety of imatinib therapyNeoplasmsKCT0003729Samsung Medical Center33
招募中
不适用
Phase II trial of regorafenib in patients with unresectable hepatocellular carcinoma after progression on first line atezolizumab plus bevacizumabKCT0006340Bundang CHA General Hospital40
未知
2 期
Phase II clinical study of TY-0201 in patients with chronic heart failureChronic heart failureJPRN-jRCT2080222593TOA EIYO LTD.40